PFIZER INC
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Total Revenues by Geography
| The following presents worldwide Total revenues by geography: | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year Ended December 31, · % Change | ||||||||||||||||||
| Worldwide · U.S. · International · Worldwide · U.S. · International | ||||||||||||||||||
| (MILLIONS) · 2023 · 2022 · 2021 · 2023 · 2022 · 2021 · 2023 · 2022 · 2021 · 23/22 · 22/21 · 23/22 · 22/21 · 23/22 · 22/21 | ||||||||||||||||||
| Operating segments: | ||||||||||||||||||
| Biopharma | $57,186 | $98,988 | $79,557 | $26,698 | $42,083 | $29,221 | $30,488 | $56,905 | $50,336 | (42) | 24 | (37) | 44 | (46) | 13 | |||
| Business Innovation | 1,310 | 1,342 | 1,731 | 390 | 390 | 524 | 920 | 952 | 1,206 | (2) | (22) | — | (26) | (3) | (21) | |||
| Total revenues | $58,496 | $100,330 | $81,288 | $27,088 | $42,473 | $29,746 | $31,408 | $57,857 | $51,542 | (42) | 23 | (36) | 43 | (46) | 12 | |||
| The following provides an analysis of the worldwide change in Total revenues by geographic areas from 2022 to 2023: | |||
|---|---|---|---|
| (MILLIONS) | Worldwide | U.S. | International |
| Operational growth/(decline): | |||
| Worldwide declines from Comirnaty | $(26,423) | $(6,370) | $(20,053) |
| Worldwide declines from Paxlovid | (17,506) | (11,803) | (5,703) |
| Worldwide growth from the Vyndaqel family, Eliquis, the Prevnar family and Inlyta, partially offset by worldwide declines from Ibrance, Xeljanz and Xtandi | 1,016 | 1,018 | (2) |
| Increase in revenues from Nurtec ODT/Vydura and Oxbryta, which were acquired in the fourth quarter of 2022 | 972 | 949 | 23 |
| Revenues from Abrysvo, primarily driven by launch of the older adult indication in the U.S. in July 2023 | 890 | 888 | 2 |
| Revenues from legacy Seagen products subsequent to the acquisition on December 14, 2023 | 120 | 120 | — |
| Other operational factors, net | 120 | (185) | 305 |
| Operational growth/(decline), net | (40,812) | (15,385) | (25,428) |
| Unfavorable impact of foreign exchange | (1,022) | — | (1,022) |
| Total revenues increase/(decrease) | $(41,834) | $(15,385) | $(26,449) |
Emerging markets revenues decreased $8.1 billion, or 40%, in 2023 to $12.0 billion from $20.1 billion in 2022, reflecting an operational decrease of $7.4 billion, or 37%, and an unfavorable impact from foreign exchange of 3%. The operational decrease in emerging markets revenues was primarily driven by declines from Comirnaty and Paxlovid, partially offset by growth from Lorbrena, Zavicefta and Eliquis.
See the Total Revenues––Selected Product Discussion section within MD&A for additional analysis.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.